Xeris Pharmaceuticals Undergoes Executive Leadership Transition
PremiumCompany AnnouncementsXeris Pharmaceuticals Undergoes Executive Leadership Transition
4M ago
Xeris Biopharma reports preliminary Q2 revenue $47M, consensus $44.89M
Premium
The Fly
Xeris Biopharma reports preliminary Q2 revenue $47M, consensus $44.89M
4M ago
Xeris Biopharma CEO Paul Edick to retire, John Shannon to succeed
Premium
The Fly
Xeris Biopharma CEO Paul Edick to retire, John Shannon to succeed
4M ago
Xeris Biopharma reports Q1 EPS (14c), consensus (12c)
PremiumThe FlyXeris Biopharma reports Q1 EPS (14c), consensus (12c)
6M ago
Xeris Biopharma enters collaboration, license agreement with Beta Bionics
Premium
The Fly
Xeris Biopharma enters collaboration, license agreement with Beta Bionics
6M ago
Xeris Biopharma enters exclusive license agreement with Beta Bionics
Premium
The Fly
Xeris Biopharma enters exclusive license agreement with Beta Bionics
6M ago
Xeris Biopharma refinances senior secured term loan agreement with Hayfin
PremiumThe FlyXeris Biopharma refinances senior secured term loan agreement with Hayfin
8M ago
Xeris Biopharma sees FY24 revenue $170M-$200M, consensus $188.01M
Premium
The Fly
Xeris Biopharma sees FY24 revenue $170M-$200M, consensus $188.01M
8M ago
Xeris Biopharma reports Q4 EPS (10c), consensus (10c)
Premium
The Fly
Xeris Biopharma reports Q4 EPS (10c), consensus (10c)
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100